Biocept (NASDAQ:BIOC) will be issuing its quarterly earnings data after the market closes on Tuesday, November 13th. Analysts expect the company to announce earnings of ($1.71) per share for the quarter.
Biocept (NASDAQ:BIOC) last announced its quarterly earnings data on Tuesday, August 14th. The medical research company reported ($2.70) EPS for the quarter, beating analysts’ consensus estimates of ($3.30) by $0.60. Biocept had a negative net margin of 642.49% and a negative return on equity of 587.80%. The company had revenue of $0.82 million during the quarter, compared to the consensus estimate of $1.09 million. On average, analysts expect Biocept to post $-9 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Shares of BIOC opened at $1.89 on Friday. Biocept has a one year low of $1.85 and a one year high of $36.00. The stock has a market capitalization of $4.57 million, a PE ratio of -0.08 and a beta of 1.82. The company has a quick ratio of 1.08, a current ratio of 1.20 and a debt-to-equity ratio of 0.42.
BIOC has been the subject of a number of analyst reports. ValuEngine raised shares of Biocept from a “hold” rating to a “buy” rating in a research report on Wednesday, August 15th. Dawson James reissued a “buy” rating on shares of Biocept in a research report on Wednesday, October 3rd. Finally, Zacks Investment Research raised shares of Biocept from a “sell” rating to a “hold” rating in a report on Monday, August 27th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Biocept has an average rating of “Buy” and an average price target of $0.92.
WARNING: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/11/11/biocept-bioc-to-release-quarterly-earnings-on-tuesday.html.
Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.
Featured Article: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.